Look back at pharma news in the week to June 5, 2020

7 June 2020

By Barbara Obstoj-Cardwell. Editor

Last week’s news included disappointing Phase III trial results for Pfizer’s drug Ibrance in the treatment of breast cancer. Gilead Sciences released data from its own study of remdesivir, now trade-named Veklury, showing the drug, though useful, did not produce statistically-significant results in the treatment of COVID-19, but analysts still see commercial success in the longer term. On a positive note, Novo Nordisk provided further evidence of the value of its semaglutide in achieving weight loss. Elsewhere, Novartis revealed last Wednesday that the US Food and Drug Administration had extended its review of the multiple sclerosis therapy ofatumumab.

Ibrance trial halt threatens Pfizer’s growth target

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK